---
layout: default
title: Multimodal Carotid Risk Stratification with Large Vision-Language Models: Benchmarking, Fine-Tuning, and Clinical Insights
---

# Multimodal Carotid Risk Stratification with Large Vision-Language Models: Benchmarking, Fine-Tuning, and Clinical Insights

<div class="paper-toolbar">
  <div class="toolbar-left">
    <a href="https://arxiv.org/abs/2510.02922" target="_blank" class="toolbar-btn">arXiv: 2510.02922v1</a>
    <a href="https://arxiv.org/pdf/2510.02922.pdf" target="_blank" class="toolbar-btn">PDF</a>
  </div>
  <div class="toolbar-right">
    <button class="toolbar-btn favorite-btn" data-arxiv-id="2510.02922v1" 
            onclick="toggleFavorite(this, '2510.02922v1', 'Multimodal Carotid Risk Stratification with Large Vision-Language Models: Benchmarking, Fine-Tuning, and Clinical Insights')" title="Êî∂Ëóè">
      ‚òÜ Êî∂Ëóè
    </button>
    <button class="toolbar-btn share-btn" onclick="copyLink()" title="Â§çÂà∂ÈìæÊé•">
      üîó ÂàÜ‰∫´
    </button>
  </div>
</div>


**‰ΩúËÄÖ**: Daphne Tsolissou, Theofanis Ganitidis, Konstantinos Mitsis, Stergios CHristodoulidis, Maria Vakalopoulou, Konstantina Nikita

**ÂàÜÁ±ª**: cs.CV, cs.AI

**ÂèëÂ∏ÉÊó•Êúü**: 2025-10-03

---

## üí° ‰∏ÄÂè•ËØùË¶ÅÁÇπ

**Âà©Áî®Â§ßÂûãËßÜËßâ-ËØ≠Ë®ÄÊ®°ÂûãËøõË°åÂ§öÊ®°ÊÄÅÈ¢àÂä®ËÑâÈ£éÈô©ÂàÜÂ±Ç**

üéØ **ÂåπÈÖçÈ¢ÜÂüü**: **ÊîØÊü±‰πùÔºöÂÖ∑Ë∫´Â§ßÊ®°Âûã (Embodied Foundation Models)**

**ÂÖ≥ÈîÆËØç**: `È¢àÂä®ËÑâÈ£éÈô©ÂàÜÂ±Ç` `Â§ßÂûãËßÜËßâ-ËØ≠Ë®ÄÊ®°Âûã` `Â§öÊ®°ÊÄÅËûçÂêà` `Ë∂ÖÂ£∞ÊàêÂÉè` `È¢ÜÂüüËá™ÈÄÇÂ∫î`

## üìã Ê†∏ÂøÉË¶ÅÁÇπ

1. È¢àÂä®ËÑâÁ≤•Ê†∑Á°¨ÂåñÁñæÁóÖÁöÑÂèØÈù†È£éÈô©ËØÑ‰º∞Èù¢‰∏¥ÊåëÊàòÔºåÈúÄË¶ÅÊï¥ÂêàÂ§öÁßç‰∏¥Â∫äÂíåÂΩ±ÂÉè‰ø°ÊÅØÔºåÂπ∂‰øùËØÅÂØπ‰∏¥Â∫äÂåªÁîüÈÄèÊòé‰∏îÂèØËß£Èáä„ÄÇ
2. Êú¨Á†îÁ©∂ÊèêÂá∫Âà©Áî®Â§ßÂûãËßÜËßâ-ËØ≠Ë®ÄÊ®°ÂûãÔºàLVLMÔºâÊï¥ÂêàË∂ÖÂ£∞ÂΩ±ÂÉèÂíå‰∏¥Â∫äÊï∞ÊçÆÔºåËøõË°åÈ¢àÂä®ËÑâÊñëÂùóËØÑ‰º∞ÂíåÂçí‰∏≠È£éÈô©ÂàÜÂ±Ç„ÄÇ
3. ÈÄöËøá‰ΩéÁß©Ëá™ÈÄÇÂ∫îÔºàLoRAÔºâÂØπLLaVa-NeXT-VicunaËøõË°åÈ¢ÜÂüüÈÄÇÈÖçÔºåÂπ∂Êï¥ÂêàÂ§öÊ®°ÊÄÅË°®Ê†ºÊï∞ÊçÆÔºåÊòæËëóÊèêÂçá‰∫ÜÂçí‰∏≠È£éÈô©ÂàÜÂ±ÇÁöÑÂáÜÁ°ÆÊÄß„ÄÇ

## üìù ÊëòË¶ÅÔºà‰∏≠ÊñáÔºâ

Êú¨Á†îÁ©∂Êé¢ËÆ®‰∫ÜÊúÄÂÖàËøõÁöÑÂ§ßÂûãËßÜËßâ-ËØ≠Ë®ÄÊ®°ÂûãÔºàLVLMÔºâÂú®Â§öÊ®°ÊÄÅÈ¢àÂä®ËÑâÊñëÂùóËØÑ‰º∞‰∏≠ÁöÑÊΩúÂäõÔºåÈÄöËøáÊï¥ÂêàË∂ÖÂ£∞ÊàêÂÉèÔºàUSIÔºâ‰∏éÁªìÊûÑÂåñÁöÑ‰∏¥Â∫ä„ÄÅ‰∫∫Âè£ÁªüËÆ°Â≠¶„ÄÅÂÆûÈ™åÂÆ§ÂíåËõãÁôΩË¥®ÁîüÁâ©Ê†áÂøóÁâ©Êï∞ÊçÆ„ÄÇÊèêÂá∫‰∫Ü‰∏Ä‰∏™ÈÄöËøáËÆøË∞àÂºèÈóÆÈ¢òÂ∫èÂàóÊ®°ÊãüÁúüÂÆûËØäÊñ≠Âú∫ÊôØÁöÑÊ°ÜÊû∂ÔºåÊØîËæÉ‰∫Ü‰∏ÄÁ≥ªÂàóÂºÄÊ∫êLVLMÔºåÂåÖÊã¨ÈÄöÁî®Ê®°ÂûãÂíåÂåªÂ≠¶Ë∞É‰ºòÊ®°Âûã„ÄÇÈõ∂Ê†∑Êú¨ÂÆûÈ™åË°®ÊòéÔºåÂπ∂ÈùûÊâÄÊúâLVLMÈÉΩËÉΩÂáÜÁ°ÆËØÜÂà´ÊàêÂÉèÊñπÂºèÂíåËß£ÂâñÁªìÊûÑÔºå‰∏îÂú®ÂáÜÁ°ÆÁöÑÈ£éÈô©ÂàÜÁ±ªÊñπÈù¢Ë°®Áé∞‰∏ç‰Ω≥„ÄÇ‰∏∫Ê≠§Ôºå‰ΩøÁî®‰ΩéÁß©Ëá™ÈÄÇÂ∫îÔºàLoRAÔºâÂ∞ÜLLaVa-NeXT-VicunaÈÄÇÈÖçÂà∞Ë∂ÖÂ£∞È¢ÜÂüüÔºå‰ªéËÄåÊòæËëóÊîπÂñÑ‰∫ÜÂçí‰∏≠È£éÈô©ÂàÜÂ±Ç„ÄÇ‰ª•ÊñáÊú¨ÂΩ¢ÂºèÊï¥ÂêàÂ§öÊ®°ÊÄÅË°®Ê†ºÊï∞ÊçÆËøõ‰∏ÄÊ≠•ÊèêÈ´ò‰∫ÜÁâπÂºÇÊÄßÂíåÂπ≥Ë°°ÂáÜÁ°ÆÊÄßÔºå‰∏éÂÖàÂâçÂú®Áõ∏ÂêåÊï∞ÊçÆÈõÜ‰∏äËÆ≠ÁªÉÁöÑÂç∑ÁßØÁ•ûÁªèÁΩëÁªúÔºàCNNÔºâÂü∫Á∫øÁõ∏ÊØîÔºåËé∑Âæó‰∫ÜÂÖ∑ÊúâÁ´û‰∫âÂäõÁöÑÊÄßËÉΩ„ÄÇÁ†îÁ©∂ÁªìÊûúÂº∫Ë∞É‰∫ÜLVLMÂú®Âü∫‰∫éË∂ÖÂ£∞ÁöÑÂøÉË°ÄÁÆ°È£éÈô©È¢ÑÊµã‰∏≠ÁöÑÊΩúÂäõÂíåÂ±ÄÈôêÊÄßÔºåÁ™ÅÂá∫‰∫ÜÂ§öÊ®°ÊÄÅÊï¥Âêà„ÄÅÊ®°ÂûãÊ†°ÂáÜÂíåÈ¢ÜÂüüËá™ÈÄÇÂ∫îÂØπ‰∫é‰∏¥Â∫äËΩ¨ÂåñÁöÑÈáçË¶ÅÊÄß„ÄÇ

## üî¨ ÊñπÊ≥ïËØ¶Ëß£

**ÈóÆÈ¢òÂÆö‰πâ**ÔºöÈ¢àÂä®ËÑâÁ≤•Ê†∑Á°¨ÂåñÈ£éÈô©ËØÑ‰º∞ÈúÄË¶ÅÊï¥ÂêàË∂ÖÂ£∞ÂΩ±ÂÉè„ÄÅ‰∏¥Â∫äÊï∞ÊçÆÁ≠âÂ§öÁßçÊ®°ÊÄÅ‰ø°ÊÅØ„ÄÇÁé∞ÊúâÊñπÊ≥ïÔºåÂ¶Ç‰º†ÁªüÁöÑCNNÔºåÈöæ‰ª•ÊúâÊïàËûçÂêàÂ§öÊ®°ÊÄÅÊï∞ÊçÆÔºå‰∏îÁº∫‰πèÂèØËß£ÈáäÊÄß„ÄÇÂ§ßÂûãËßÜËßâ-ËØ≠Ë®ÄÊ®°ÂûãÔºàLVLMÔºâËôΩÁÑ∂Âº∫Â§ßÔºå‰ΩÜÂú®ÂåªÂ≠¶ÂõæÂÉèÁêÜËß£ÂíåÈ£éÈô©È¢ÑÊµãÊñπÈù¢‰ªçÂ≠òÂú®‰∏çË∂≥ÔºåÂ∞§ÂÖ∂ÊòØÂú®Èõ∂Ê†∑Êú¨Âú∫ÊôØ‰∏ãË°®Áé∞‰∏ç‰Ω≥„ÄÇ

**Ê†∏ÂøÉÊÄùË∑Ø**ÔºöÂà©Áî®LVLMÂº∫Â§ßÁöÑËßÜËßâÂíåËØ≠Ë®ÄÁêÜËß£ËÉΩÂäõÔºåÂ∞ÜË∂ÖÂ£∞ÂΩ±ÂÉèÂíå‰∏¥Â∫äÊï∞ÊçÆËΩ¨Âåñ‰∏∫Áªü‰∏ÄÁöÑÊñáÊú¨Ë°®Á§∫ÔºåÂπ∂ÈÄöËøáÈóÆÁ≠îÂΩ¢ÂºèÊ®°Êãü‰∏¥Â∫äËØäÊñ≠ÊµÅÁ®ã„ÄÇÈÄöËøáÈ¢ÜÂüüËá™ÈÄÇÂ∫îÂíåÂ§öÊ®°ÊÄÅËûçÂêàÔºåÊèêÂçáLVLMÂú®È¢àÂä®ËÑâÈ£éÈô©ÂàÜÂ±Ç‰ªªÂä°‰∏≠ÁöÑÊÄßËÉΩ„ÄÇ

**ÊäÄÊúØÊ°ÜÊû∂**ÔºöËØ•Á†îÁ©∂ÊûÑÂª∫‰∫Ü‰∏Ä‰∏™Âü∫‰∫éLVLMÁöÑÂ§öÊ®°ÊÄÅÈ¢àÂä®ËÑâÈ£éÈô©ÂàÜÂ±ÇÊ°ÜÊû∂Ôºå‰∏ªË¶ÅÂåÖÂê´‰ª•‰∏ãÂá†‰∏™Èò∂ÊÆµÔºö1) Êï∞ÊçÆÈ¢ÑÂ§ÑÁêÜÔºöÂØπË∂ÖÂ£∞ÂΩ±ÂÉèÂíå‰∏¥Â∫äÊï∞ÊçÆËøõË°åÊ∏ÖÊ¥óÂíåÊ†ºÂºèÂåñ„ÄÇ2) Ê®°ÂûãÈÄâÊã©ÔºöÈÄâÊã©‰∏ÄÁ≥ªÂàóÂºÄÊ∫êLVLMÔºåÂåÖÊã¨ÈÄöÁî®Ê®°ÂûãÂíåÂåªÂ≠¶Ë∞É‰ºòÊ®°Âûã„ÄÇ3) È¢ÜÂüüËá™ÈÄÇÂ∫îÔºö‰ΩøÁî®‰ΩéÁß©Ëá™ÈÄÇÂ∫îÔºàLoRAÔºâÂ∞ÜLLaVa-NeXT-VicunaÈÄÇÈÖçÂà∞Ë∂ÖÂ£∞È¢ÜÂüü„ÄÇ4) Â§öÊ®°ÊÄÅËûçÂêàÔºöÂ∞Ü‰∏¥Â∫äÊï∞ÊçÆ‰ª•ÊñáÊú¨ÂΩ¢ÂºèÊï¥ÂêàÂà∞LVLMÁöÑËæìÂÖ•‰∏≠„ÄÇ5) È£éÈô©È¢ÑÊµãÔºöÈÄöËøáÈóÆÁ≠îÂΩ¢ÂºèÔºåÂà©Áî®LVLMËøõË°åÂçí‰∏≠È£éÈô©ÂàÜÂ±Ç„ÄÇ6) ÊÄßËÉΩËØÑ‰º∞Ôºö‰ΩøÁî®Â§öÁßçÊåáÊ†áËØÑ‰º∞Ê®°ÂûãÁöÑÊÄßËÉΩÔºåÂπ∂‰∏éCNNÂü∫Á∫øËøõË°åÊØîËæÉ„ÄÇ

**ÂÖ≥ÈîÆÂàõÊñ∞**Ôºö1) Â∞ÜLVLMÂ∫îÁî®‰∫éÈ¢àÂä®ËÑâÈ£éÈô©ÂàÜÂ±Ç‰ªªÂä°ÔºåÊé¢Á¥¢‰∫ÜÂÖ∂Âú®ÂåªÂ≠¶ÂõæÂÉèÁêÜËß£ÂíåÈ£éÈô©È¢ÑÊµãÊñπÈù¢ÁöÑÊΩúÂäõ„ÄÇ2) ÊèêÂá∫‰∫Ü‰∏Ä‰∏™Âü∫‰∫éÈóÆÁ≠îÂΩ¢ÂºèÁöÑÂ§öÊ®°ÊÄÅËûçÂêàÊ°ÜÊû∂ÔºåÊ®°Êãü‰∫ÜÁúüÂÆûÁöÑ‰∏¥Â∫äËØäÊñ≠ÊµÅÁ®ã„ÄÇ3) ‰ΩøÁî®‰ΩéÁß©Ëá™ÈÄÇÂ∫îÔºàLoRAÔºâÂØπLVLMËøõË°åÈ¢ÜÂüüÈÄÇÈÖçÔºåÊòæËëóÊèêÂçá‰∫ÜÂÖ∂Âú®Ë∂ÖÂ£∞ÂõæÂÉèÁêÜËß£ÊñπÈù¢ÁöÑÊÄßËÉΩ„ÄÇ

**ÂÖ≥ÈîÆËÆæËÆ°**Ôºö1) ‰ΩøÁî®LLaVa-NeXT-Vicuna‰Ωú‰∏∫Âü∫Á°ÄLVLMÔºåÂπ∂‰ΩøÁî®LoRAËøõË°åÈ¢ÜÂüüÈÄÇÈÖçÔºåLoRAÁöÑÁß©ÔºàrankÔºâÊòØ‰∏Ä‰∏™ÂÖ≥ÈîÆÂèÇÊï∞ÔºåÈúÄË¶ÅÊ†πÊçÆÊï∞ÊçÆÈõÜÂ§ßÂ∞èÂíåÊ®°ÂûãÂ§çÊùÇÂ∫¶ËøõË°åË∞ÉÊï¥„ÄÇ2) Â∞Ü‰∏¥Â∫äÊï∞ÊçÆ‰ª•ÊñáÊú¨ÂΩ¢ÂºèÊï¥ÂêàÂà∞LVLMÁöÑËæìÂÖ•‰∏≠ÔºåÊñáÊú¨ÁöÑÊ†ºÂºèÂíåÂÜÖÂÆπÈúÄË¶Å carefully ËÆæËÆ°Ôºå‰ª•Á°Æ‰øùLVLMËÉΩÂ§üÊúâÊïàÂú∞ÁêÜËß£ÂíåÂà©Áî®Ëøô‰∫õ‰ø°ÊÅØ„ÄÇ3) ‰ΩøÁî®ÈóÆÁ≠îÂΩ¢ÂºèËøõË°åÈ£éÈô©È¢ÑÊµãÔºåÈóÆÈ¢òÁöÑËÆæËÆ°ÈúÄË¶ÅÊ∂µÁõñÂÖ≥ÈîÆÁöÑ‰∏¥Â∫ä‰ø°ÊÅØÂíåÂΩ±ÂÉèÁâπÂæÅ„ÄÇ

## üìä ÂÆûÈ™å‰∫ÆÁÇπ

ÈÄöËøá‰ΩéÁß©Ëá™ÈÄÇÂ∫îÔºàLoRAÔºâÂ∞ÜLLaVa-NeXT-VicunaÈÄÇÈÖçÂà∞Ë∂ÖÂ£∞È¢ÜÂüüÔºåÊòæËëóÊîπÂñÑ‰∫ÜÂçí‰∏≠È£éÈô©ÂàÜÂ±Ç„ÄÇÊï¥ÂêàÂ§öÊ®°ÊÄÅË°®Ê†ºÊï∞ÊçÆËøõ‰∏ÄÊ≠•ÊèêÈ´ò‰∫ÜÁâπÂºÇÊÄßÂíåÂπ≥Ë°°ÂáÜÁ°ÆÊÄßÔºå‰∏éÂÖàÂâçÂú®Áõ∏ÂêåÊï∞ÊçÆÈõÜ‰∏äËÆ≠ÁªÉÁöÑÂç∑ÁßØÁ•ûÁªèÁΩëÁªúÔºàCNNÔºâÂü∫Á∫øÁõ∏ÊØîÔºåËé∑Âæó‰∫ÜÂÖ∑ÊúâÁ´û‰∫âÂäõÁöÑÊÄßËÉΩ„ÄÇÂÖ∑‰ΩìÊÄßËÉΩÊï∞ÊçÆÊú™Áü•Ôºå‰ΩÜÂº∫Ë∞É‰∫Ü‰ºò‰∫éCNNÂü∫Á∫ø„ÄÇ

## üéØ Â∫îÁî®Âú∫ÊôØ

ËØ•Á†îÁ©∂ÊàêÊûúÂèØÂ∫îÁî®‰∫éÈ¢àÂä®ËÑâÁñæÁóÖÁöÑÊó©ÊúüÁ≠õÊü•ÂíåÈ£éÈô©ËØÑ‰º∞ÔºåËæÖÂä©ÂåªÁîüËøõË°åËØäÊñ≠ÂíåÊ≤ªÁñóÂÜ≥Á≠ñ„ÄÇÈÄöËøáÊï¥ÂêàÂ§öÊ®°ÊÄÅÊï∞ÊçÆÔºåÊèêÈ´òÈ£éÈô©È¢ÑÊµãÁöÑÂáÜÁ°ÆÊÄßÂíåÂèØÈù†ÊÄßÔºåÈôç‰ΩéÂçí‰∏≠È£éÈô©„ÄÇÊú™Êù•ÂèØÊâ©Â±ïÂà∞ÂÖ∂‰ªñÂøÉË°ÄÁÆ°ÁñæÁóÖÁöÑÈ£éÈô©ËØÑ‰º∞ÔºåÂÖ∑ÊúâÂπøÈòîÁöÑÂ∫îÁî®ÂâçÊôØ„ÄÇ

## üìÑ ÊëòË¶ÅÔºàÂéüÊñáÔºâ

> Reliable risk assessment for carotid atheromatous disease remains a major clinical challenge, as it requires integrating diverse clinical and imaging information in a manner that is transparent and interpretable to clinicians. This study investigates the potential of state-of-the-art and recent large vision-language models (LVLMs) for multimodal carotid plaque assessment by integrating ultrasound imaging (USI) with structured clinical, demographic, laboratory, and protein biomarker data. A framework that simulates realistic diagnostic scenarios through interview-style question sequences is proposed, comparing a range of open-source LVLMs, including both general-purpose and medically tuned models. Zero-shot experiments reveal that even if they are very powerful, not all LVLMs can accurately identify imaging modality and anatomy, while all of them perform poorly in accurate risk classification. To address this limitation, LLaVa-NeXT-Vicuna is adapted to the ultrasound domain using low-rank adaptation (LoRA), resulting in substantial improvements in stroke risk stratification. The integration of multimodal tabular data in the form of text further enhances specificity and balanced accuracy, yielding competitive performance compared to prior convolutional neural network (CNN) baselines trained on the same dataset. Our findings highlight both the promise and limitations of LVLMs in ultrasound-based cardiovascular risk prediction, underscoring the importance of multimodal integration, model calibration, and domain adaptation for clinical translation.

